Bayer (BAYRY) announced that it has met the primary endpoint of radiological progression-free survival (rPFS) in its late-stage study evaluating the safety and efficacy of darolutamide in combination with androgen deprivation therapy (ADT) without docetaxelin patients with metastatic hormone-sensitive prostate cancer (mHSPC).The phase III ARANOTE study enrolled 669 patients who were randomized to receive 600mg of darolutamide twice daily or matching placebo in addition to ADT.Per the data readout, the combo ...